55
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?

, &
Pages 495-505 | Received 21 May 2005, Published online: 09 Jul 2009

References

  • Roehrborn CG, McConnel JD, Barry MJ, Benaim E, Bruskewitz RC, Blute ML, et al Guideline on the management of benign prostatic hyperplasia (BPH). American Urological Association Education and Research, Inc.; 2003, www.auanet.org/guidelines/bph.cfm.
  • Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, Schain M, et al. Feedback microwave thermotherapy versus TURP for clinical BPH—a randomized controlled multicenter study. Urology 2002; 60: 292–9
  • De la Rosette JJMCH, Floratos DL, Severens JL, Kiemeney LALM, Debruyne FMJ, Pilar Laguna M. Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. Br J Urol 2003; 92: 713–8
  • Kobelt G, Spånberg A, Mattiasson A. The cost of feedback microwave thermotherapy compared with transurethral resection of the prostate for treating benign prostatic hyperplasia. BJU Int 2004; 93: 543–8
  • Waldén M, Acosta S, Carlsson P, Pettersson S, Dahlstrand C. A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: a two-year followup. Scand J Urol Nephrol 1998; 32: 204–10
  • Djavan B, Seitz C, Roehrborn CG, Remzi M, Fakhari M, Waldert M, et al. Targeted transurethal microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcome at 18 months. Urology 2001; 57: 66–70
  • Annemans L, Genesté B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health 2000; 3: 427–34
  • Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health 2001; 3: 225–50
  • LFN. General guidelines for economic evaluations from the Pharmaceutical Benefits Board, Vol. LFNAR 2003:2. Stockholm: The Pharmaceutical Benefits Board, Läkemedelsförmånsnämnden; 2003.
  • Dahlstrand C. Mikrovågsbehandling med högenergi vid godartad prostatahyperplasi. Ett bra och säkert terapival—för både patienten och sjukvården. Läkartidningen 2003; 100: 2678–83
  • D'Ancona FC, Francisca EA, Debruyne FM, de la Rosette JJ. High-energy transurethral microwave thermotherapy in men with lower urinary tract symptoms. J Endourol 1997; 11: 285–9
  • Floratos DL, Kiemeney LA, Rossi C, Kortmann BB, Debruyne FM, de la Rosette JJ. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001; 165: 1533–8
  • Francisca EA, d'Ancona FC, Hendriks JCM, Kiemeney LA, Debruyne FM, de la Rosette JJ. A randomized study comparing high-energy TUMT to TURP: quality of life results. Eur Urol 2000; 38: 569–75
  • Mattiasson A, de la Rosette J, Graber S, Gravas S, Laguna P, Larson T. Korrelationer mellan reduktioner i prostatavolym och olika studievariabler efter mikrovågsbehandling. Svenska Läkarsällskapets handlingar Hygiea 2003; 112: 347
  • Ramsey EW, Miller PD, Parsons K. Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urolix T3 device. World J Urol 1998; 16: 96–101
  • Djavan B, Roehrborn CG, Shariat S, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alphablocker treatment of patients with benign prostatic hyperplasia. J Urol 1999; 161: 139–43
  • Trueman P, Hood SC, Nayak USL, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed “benign prostatic hyperplasia”, and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999; 83: 410–5
  • Kind P. The EuroQol instrument: an index of health related quality of life. Quality of life and pharmacoeconomics in clinical trials, B Spilker. Lippincott-Raven Publishers, Philadelphia, PA 1996; 191–201
  • Kobelt G. Health economics. An introduction to economic evaluation. Office of Health Economics, London 1996; 1–36
  • Statistics Sweden. Life tables: Statistical Yearbook of Sweden, 2003, Vol. 89. Stockholm: Statistics Sweden; 2002.
  • Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, OxfordUK 1997
  • FASS. FASS 2003 (Pharmaceutical Specialties in Sweden). Stockholm: Läkemedelsindustriföreningen; 2003.
  • MIS. Medical Index Sweden. Stockholm: Läkemedelsstatistik AB; 2002.
  • Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddard GL. Methods for the economic evaluation of health care programmes. Oxford University Press, OxfordUK 2004
  • Persson U, Hjelmgren J. Hälso-och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003; 100: 3436–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.